RCS - Arecor Therapeutics - Arecor presents positive data for AT247 at ADA

Arecor TherapeuticsAnnouncement

26/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230626:nRSZ7924Da&default-theme=true

RNS Number : 7924D  Arecor Therapeutics PLC  26 June 2023

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

 

Arecor presents positive data from US phase I clinical trial of ultra-rapid
acting insulin candidate AT247 delivered via insulin pump at ADA annual
meeting

 

-      Data presented at the American Diabetes Association 83(rd)
Scientific Sessions

-      AT247 delivers significantly accelerated insulin absorption and
early exposure (PK profile) compared with NovoLog® and Fiasp®

-      Further supports potential to enable more effective disease
management for people with Type I diabetes via fully automated closed loop
insulin pump delivery (artificial pancreas)

 

Cambridge, UK, 26 June 2023: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, today announces that positive results from its second Phase I clinical
trial investigating ultra-rapid acting insulin product candidate, AT247, have
been shared in a poster presentation at the American Diabetes Association
(ADA) 83(rd) Scientific Sessions meeting, being held until today in San Diego,
California and online.

 

The poster, "Double blind cross over study of ultra-rapid AT247 compared with
NovoLog® and Fiasp® during continuous subcutaneous infusion (CSII) assessed
by a hyperinsulinemic euglycemic clamp", is displayed in the meeting's Poster
Hall and available as an ePoster for virtual attendees.

 

Dr Marcus Hompesch, MD. President and Chief Executive Officer of ProSciento
Inc, said: "AT247 has demonstrated faster insulin absorption when delivered by
continuous infusion via an insulin pump, compared to other rapid acting
insulins currently available to patients. Its PK profile offers the potential
to further improve blood glucose control, and may play an important role in
facilitating a fully closed loop artificial pancreas - a life changing
treatment approach for people living with diabetes."

 

Sarah Howell, Chief Executive Officer of Arecor, added: "These data reinforce
AT247's potential to enable even more effective disease management for people
with Type I diabetes. The availability of a truly ultra-rapid acting insulin
will be a key component in the move towards a fully closed loop artificial
pancreas system, a potentially life changing treatment option for people
living with diabetes, improving health outcomes and reducing the significant
burden of managing this chronic disease. With AT247, Arecor has the ability to
significantly advance the diabetic treatment landscape and, ultimately,
deliver better health outcomes for patients."

 

AT247 is a 100U/mL ultra-rapid acting novel formulation of insulin that has
been designed to accelerate the absorption of insulin following subcutaneous
injection, to enable more effective management of blood glucose levels for
people living with diabetes.

 

In the Phase I trial, faster absorption of AT247 resulted in higher early
insulin exposure than with gold standard insulins NovoLog® and Fiasp®
following bolus dose delivery during continuous subcutaneous infusion. The
demonstrated PK profile of AT247 supports further investigation into its
potential to further improve automated insulin delivery and builds on the
superior PK/PD profile of a single AT247 dose compared with NovoLog® and
Fiasp®, previously demonstrated in an earlier Phase I study.

 

Headline results from the ARE-AT247-103 clinical trial were announced by the
Company
(https://otp.tools.investis.com/clients/uk/arecor_therapeutics_plc/rns/regulatory-story.aspx?cid=2671&newsid=1633981)
on 11 October 2022.

 

-ENDS-

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray          Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABUGDLBUDDGXX